BiotechTube

CG0070 + Nivolumab

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Muscle-Invasive Bladder Carcinoma

Conditions

Muscle-Invasive Bladder Carcinoma, Bladder Cancer

Trial Timeline

Oct 26, 2020 → Jul 25, 2024

NCT ID
NCT04610671

About CG0070 + Nivolumab

CG0070 + Nivolumab is a phase 1 stage product being developed by CG Oncology for Muscle-Invasive Bladder Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04610671. Target conditions include Muscle-Invasive Bladder Carcinoma, Bladder Cancer.

What happened to similar drugs?

0 of 3 similar drugs in Muscle-Invasive Bladder Carcinoma were approved

Approved (0) Terminated (0) Active (3)
🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
🔄Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
🔄AtezolizumabRochePhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04610671Phase 1Completed

Competing Products

12 competing products in Muscle-Invasive Bladder Carcinoma

See all competitors
ProductCompanyStageHype Score
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
44
Durvalumab (Imfinzi) + TremelimumabAstraZenecaPhase 2
27
Pembrolizumab + GemcitabineMerckPhase 2
39
Chemotherapy + Immunotherapy Induction + Immunotherapy MaintenanceMerckPhase 2
42
Autogene Cevumeran + Nivolumab + SalineRochePhase 2
42
AtezolizumabRochePhase 3
44
Nivolumab + Nab-paclitaxel + NivolumabBristol Myers SquibbPhase 2
31
Cretostimogene GrenadenorepvecCG OncologyPhase 2
39
AU-011Aura BiosciencesPhase 1
26
REOLYSIN® + Gemcitabine + CisplatinOncolytics BiotechPhase 1
11